Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Bilastine on Driving Performance in Allergic Rhinitis and Urticaria
NCT02576041Phase 4Completed
- Sponsor
- Menarini Group
- Start
- Oct 2015
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bilastine in allergic rhinitis (AR) and urticaria, sponsored by Menarini Group. Primary endpoint: Standard Deviation Lateral Position. Started Oct 2015; status: completed.
02
Drugs
bilastine
03
Conditions
allergic rhinitis (AR)urticaria
Beyond the preview
Go deeper on NCT02576041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02576041.